A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2710|40|4|391-397

ISSN： 0269-4727

Source： JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol.40, Iss.4, 2015-08, pp. : 391-397

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Second-Generation Tyrosine Kinase Inhibitors in the Post-Transplant Period in Patients with Chronic Myeloid Leukemia or Philadelphia-Positive Acute Lymphoblastic Leukemia

By  

Acta Haematologica, Vol. 122, Iss. 1, 2009-07 ,pp. : 6-10

Karger

Access to resources Recommend Favorite

Treating Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors

By  

Acta Haematologica, Vol. 130, Iss. 3, 2013-06 ,pp. : 192-195

Karger

Access to resources Recommend Favorite

Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: The Challenge That Lies Ahead

By  

Acta Haematologica, Vol. 136, Iss. 1, 2016-05 ,pp. : 43-44

Karger

Access to resources Recommend Favorite

CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib‐resistant chronic myeloid leukaemia

By  

THE JOURNAL OF PATHOLOGY, Vol. 237, Iss. 1, 2015-09 ,pp. : 14-24

John Wiley & Sons Inc

Access to resources Recommend Favorite

Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 683-688

John Wiley & Sons Inc

Access to resources Recommend Favorite